Omeros (NASDAQ:OMER) Earning Somewhat Favorable Media Coverage, Study Shows

Press coverage about Omeros (NASDAQ:OMER) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Omeros earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.7822881111472 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:

Shares of Omeros (NASDAQ OMER) opened at $19.73 on Friday. Omeros has a twelve month low of $8.71 and a twelve month high of $27.09. The firm has a market capitalization of $947.11, a price-to-earnings ratio of -15.29 and a beta of 3.56. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. The business had revenue of $21.66 million during the quarter, compared to analysts’ expectations of $17.82 million. During the same quarter in the previous year, the business earned ($0.34) EPS. The business’s revenue for the quarter was up 91.9% on a year-over-year basis. equities analysts forecast that Omeros will post -0.98 earnings per share for the current fiscal year.

Several research firms have weighed in on OMER. Maxim Group set a $24.00 price target on Omeros and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. HC Wainwright set a $30.00 price target on Omeros and gave the stock a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research downgraded Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 target price on shares of Omeros in a research report on Tuesday, November 28th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $34.14.

WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Insider Buying and Selling by Quarter for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.

Leave a Reply